Differential Responses to IFN-α Subtypes in Human T Cells and Dendritic Cells 12

Type I IFNs (IFN-αβ) constitute a family of cytokines that have important antiviral and immunoregulatory properties and have been successfully used in the treatment of a wide variety of diseases. There are 12 functional human IFN-α subtypes and one IFN-β subtype that signal through the common cell surface IFN-αβR. To date, virtually no information is available on the specificity of IFN-α responses in immune cells. In this study, Janus kinase/STAT signaling and transcriptional responses to selected IFN-α subtypes in human T cells and dendritic cells were analyzed. Evidence for IFN-α subtype and cell type specificity was found. Also, differences between kinetics of expression of IFN-stimulated genes (ISGs) and in the requirements of individual ISGs for additional signaling pathways were observed. In particular, IFN-γ-inducible protein-10 (IP-10), a key chemokine in Th1-type inflammatory diseases, was differentially regulated. In dendritic cells, it was highly induced by IFN-α2 and IFN-α21 but much less efficiently by IFN-α1. It was only marginally induced by these subtypes in T cells. In marked contrast to other ISGs analyzed, optimum induction of IP-10 was dependent on activation of p38 kinase(s). The observed variations (subtype-, cell type-, and ISG-related differentials) provide further insight into the complexity and plasticity of the IFN-αβ response. Furthermore, the novel observation that IFN-α1 poorly induces IP-10 is potentially of clinical importance, because this subtype may be more beneficial in cases where Th1-mediated side effects (e.g., exacerbation of autoimmune diseases) are not desirable.

[1]  B. Williams,et al.  Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .

[2]  C. Biron Interferons α and β as Immune Regulators—A New Look , 2001 .

[3]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[4]  J. O’Shea,et al.  Inducible Expression of Stat4 in Dendritic Cells and Macrophages and Its Critical Role in Innate and Adaptive Immune Responses1 , 2001, The Journal of Immunology.

[5]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Y Oikawa,et al.  Elevated serum IP-10 levels observed in type 1 diabetes. , 2001, Diabetes care.

[7]  H. Thomas,et al.  Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[8]  P. Sehgal The interferon genes. , 1982, Biochimica et biophysica acta.

[9]  W. Yeow,et al.  Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. , 1998, Journal of immunology.

[10]  S. Pestka,et al.  Specific molecular activities of recombinant and hybrid leukocyte interferons. , 1982, The Journal of biological chemistry.

[11]  L. Rogge,et al.  Regulation of the IL‐12/IL‐12R axis: a critical step in T‐helper cell differentiation and effector function , 1999, Immunological reviews.

[12]  A. Lukashin,et al.  Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[13]  K. Zoon,et al.  Purification and characterization of multiple components of human lymphoblastoid interferon-alpha. , 1992, The Journal of biological chemistry.

[14]  P. A. Tilbrook,et al.  Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. , 2003, Blood.

[15]  E. Bosi,et al.  Fulminant autoimmune Type 1 diabetes during interferon‐alpha therapy: a case of Th1‐mediated disease? , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[16]  S. Nagata,et al.  Different binding of human interferon alpha 1 and alpha 2 to common receptors on human and bovine cells. Studies with recombination interferons produced in Escherichia coli. , 1983, The Journal of biological chemistry.

[17]  C. Griffiths,et al.  PSORIASIS AND INTERFERON , 1986, The Lancet.

[18]  L. Pfeffer,et al.  Interferon α/β Promotes Cell Survival by Activating Nuclear Factor κB through Phosphatidylinositol 3-Kinase and Akt* , 2001, The Journal of Biological Chemistry.

[19]  S. Gupta,et al.  IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. , 1999, Journal of immunology.

[20]  G. Stark,et al.  Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon‐alpha and ‐gamma signal transduction pathways. , 1993, The EMBO journal.

[21]  J. de Maeyer-Guignard,et al.  Type I interferons. , 1998, International reviews of immunology.

[22]  E. Coccia,et al.  IFN-αβ Released by Mycobacterium tuberculosis-Infected Human Dendritic Cells Induces the Expression of CXCL10: Selective Recruitment of NK and Activated T Cells 1 , 2003, The Journal of Immunology.

[23]  F. Belardelli,et al.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. , 2001, Immunity.

[24]  S. Harroch,et al.  Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN‐alpha and IFN‐beta. , 1994, The EMBO journal.

[25]  Y. Ohmori,et al.  The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. , 1995, Journal of immunology.

[26]  M. Dziejman,et al.  IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.

[27]  B. Williams,et al.  p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons , 1999, The EMBO journal.

[28]  E. Fish,et al.  Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. , 1983, Biochemical and biophysical research communications.

[29]  H. Keirstead,et al.  Neutralization of the Chemokine CXCL10 Reduces Inflammatory Cell Invasion and Demyelination and Improves Neurological Function in a Viral Model of Multiple Sclerosis1 , 2001, The Journal of Immunology.

[30]  J. Farrar,et al.  Type I interferons and T helper development. , 2000, Immunology today.

[31]  T. Taniguchi,et al.  A weak signal for strong responses: interferon-alpha/beta revisited , 2001, Nature Reviews Molecular Cell Biology.

[32]  J. Schwartzman,et al.  IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. , 2000, Immunity.

[33]  D. Näf,et al.  Different pathways mediate virus inducibility of the human IFN-α1 and IFN-β genes , 1990, Cell.

[34]  D. Cantrell,et al.  IL‐12 selectively regulates STAT4 via phosphatidylinositol 3‐kinase and Ras‐independent signal transduction pathways , 2000, European journal of immunology.

[35]  R. Rees,et al.  Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. , 1996, Journal of Immunology.

[36]  D. Levy,et al.  Differential viral induction of distinct interferon‐α genes by positive feedback through interferon regulatory factor‐7 , 1998, The EMBO journal.

[37]  J. Platt,et al.  Transplantation of discordant xenografts: a challenge revisited. , 1996, Immunology today.

[38]  G. Foster,et al.  Human type I interferons differ greatly in their effects on the proliferation of primary B cells. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[39]  G. Stark,et al.  Requirement of Phosphoinositide 3-Kinase and Akt for Interferon-β-mediated Induction of the β-R1(SCYB11) Gene* , 2002, The Journal of Biological Chemistry.

[40]  K. Cantell,et al.  Differential expression of human interferon genes. , 1984, Nucleic acids research.

[41]  N. Roberts,et al.  Different antiviral spectra of human macrophage interferon activities , 1983, Nature.

[42]  J. Galon,et al.  Stat4 Is Expressed in Activated Peripheral Blood Monocytes, Dendritic Cells, and Macrophages at Sites of Th1-Mediated Inflammation1 , 2000, The Journal of Immunology.

[43]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  K. Öberg,et al.  Autoimmune Phenomena in Patients with Malignant Carcinoid Tumors During Interferon-α Treatment , 1991 .

[45]  K. Zoon,et al.  Evidence for multiple binding sites for several components of human lymphoblastoid interferon-alpha. , 1993, The Journal of biological chemistry.

[46]  L. Platanias,et al.  Differential Use of the βL Subunit of the Type I Interferon (IFN) Receptor Determines Signaling Specificity for IFNα2 and IFNβ* , 1998, The Journal of Biological Chemistry.

[47]  P. Koskinen,et al.  Interferon- Activates Multiple STAT Proteins and Upregulates Proliferation-Associated IL-2R, c-myc, and pim-1 Genes in Human T Cells , 1999 .

[48]  Sagie Schif-Zuck,et al.  Targeting the Function of IFN-γ-Inducible Protein 10 Suppresses Ongoing Adjuvant Arthritis1 , 2002, The Journal of Immunology.

[49]  Fritz Aberger,et al.  Cell-type and Donor-specific Transcriptional Responses to Interferon-α , 2002, The Journal of Biological Chemistry.

[50]  G. Uzé,et al.  Shared receptor components but distinct complexes for alpha and beta interferons. , 1998, Journal of molecular biology.

[51]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[52]  B. Cohen,et al.  The human interferon α β receptor: Characterization and molecular cloning , 1994, Cell.

[53]  E. Petricoin,et al.  Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. , 1995, Science.

[54]  K. Simon,et al.  Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  P. Lebon,et al.  Constitutive expression of specific interferon isotypes in peripheral blood leukocytes from normal individuals and in promonocytic U937 cells , 1996, Journal of leukocyte biology.

[56]  P. Moore,et al.  Virus-specific Activation of a Novel Interferon Regulatory Factor, IRF-5, Results in the Induction of Distinct Interferon α Genes* , 2001, The Journal of Biological Chemistry.

[57]  G. Uzé,et al.  Shared receptor components but distinct complexes for α and β interferons 1 1Edited by M. Yaniv , 1998 .

[58]  S. Akira,et al.  Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha. , 1996, Journal of immunology.

[59]  R. Herberman Effect of α-interferons on immune function , 1997 .

[60]  A. Gottlieb,et al.  Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques , 1988, The Journal of experimental medicine.

[61]  G. Lutfalla,et al.  Genetic transfer of a functional human interferon α receptor into mouse cells: Cloning and expression of its c-DNA , 1990, Cell.

[62]  L. Platanias,et al.  The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. , 2000, The Journal of biological chemistry.

[63]  D. Patel,et al.  CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. , 2001, Clinical immunology.

[64]  A. Sing,et al.  Bacterial Induction of Beta Interferon in Mice Is a Function of the Lipopolysaccharide Component , 2000, Infection and Immunity.

[65]  G. Stark,et al.  Mutant U5A cells are complemented by an interferon‐alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. , 1995, The EMBO journal.

[66]  Andrew D. Luster,et al.  γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins , 1985, Nature.

[67]  C. Bogdan,et al.  Type 1 Interferon (IFNα/β) and Type 2 Nitric Oxide Synthase Regulate the Innate Immune Response to a Protozoan Parasite , 1998 .

[68]  L. Platanias,et al.  Activation of the p 38 Mitogen-activated Protein Kinase by Type I Interferons , 1999 .

[69]  G. Foster,et al.  Are all Type I human interferons equivalent? , 1998, Journal of viral hepatitis.

[70]  J. Hiscott,et al.  Selective DNA Binding and Association with the CREB Binding Protein Coactivator Contribute to Differential Activation of Alpha/Beta Interferon Genes by Interferon Regulatory Factors 3 and 7 , 2000, Molecular and Cellular Biology.

[71]  S. Nagata,et al.  Target cell specificity of two species of human interferon-alpha produced in Escherichia coli and of hybrid molecules derived from them. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[72]  S. Pestka The human interferon-alpha species and hybrid proteins. , 1997, Seminars in oncology.

[73]  L. Platanias,et al.  Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. , 1996, The Journal of biological chemistry.

[74]  F. Belardelli,et al.  The neglected role of type I interferon in the T-cell response: implications for its clinical use. , 1996, Immunology today.